GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MBX Biosciences Inc (NAS:MBX) » Definitions » Inventories, Other

MBX (MBX Biosciences) Inventories, Other : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is MBX Biosciences Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. MBX Biosciences's other inventories for the quarter that ended in Dec. 2024 was $0.00 Mil.

MBX Biosciences Inventories, Other Historical Data

The historical data trend for MBX Biosciences's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MBX Biosciences Inventories, Other Chart

MBX Biosciences Annual Data
Trend Dec22 Dec23 Dec24
Inventories, Other
- - -

MBX Biosciences Quarterly Data
Dec22 Sep23 Dec23 Jun24 Sep24 Dec24
Inventories, Other Get a 7-Day Free Trial - - - - -

MBX Biosciences Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

MBX Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MBX Biosciences Inc (NAS:MBX) » Definitions » Inventories, Other
Comparable Companies
TSVT PRME SLRN TERN GOSS AVIR SEPN ANNX MNPR CDTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032
Website
https://www.mbxbio.com
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.